Industry news that matters to you.  Learn more

Archives for February 2012

Cepmed Launches Online Personalized Medicine Portal

The Centre of Excellence in Personalized Medicine (Cepmed), announced recently that they have launched a web-based Personalized Medicine Portal for Canadians and joined DNA Direct by Medco’s Genomic Medicine Network (GMN).

OGT Signs Licensing Deal for Colorectal Cancer Biomarkers

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today that it has entered into an exclusive licensing agreement with Inven2, the technology transfer office at Oslo University Hospital (OUS) and University of Oslo (UiO), for 12 highly promising colorectal cancer tissue biomarkers.

Apceth and Indivumed to Develop Biomarker Platform for Targeted Cellular Therapies

apceth GmbH & Co. KG, located in Munich, Germany, and Indivumed GmbH, based in Hamburg, Germany, have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and/or gene therapeutics. The goal is to predict the response of a targeted cellular/gene therapy in different cancer types and to stratify patients to provide a more individualized cancer treatment with apceth’s innovative cell and cell-based gene therapeutics. A reliable biomarker platform will enable oncologists to identify those patients who will most likely benefit from the treatment with apceth’s therapeutics, thus establishing a unique and truly personalized therapeutic approach adapted to the needs of each cancer patient.

Dako Enters into an Additional CDx Collaboration with Amgen

Dako, a world leading independent cancer diagnostic supplier with 45 years of experience in pathology, announced today that it has entered into a new collaboration agreement with Amgen Inc. on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.

Fighting Breast Cancer: New EU-funded Biomarker Project Kicks Off

A new EU-funded biomarker project that aims to get breast cancer therapy more tailored to individual patients has just got under way. By ensuring that breast cancer therapy is specifically designed with an individual patient in mind, medical practitioners can bypass ineffective treatments – saving both valuable time and energy.